Across TCGA pan-cancer cohorts, MIR1179 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated MIR1179 data layer compared with 1 for mutation status.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR1179 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR1179 expression acts as an unfavorable survival marker, although some lineages such as PAAD and OV show a favorable association.
STAD, TGCT, and THCA are the cancer types where MIR1179 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.